Trending

LEO Pharma

Almirall gets in on the eczema action

Almirall gets in on the eczema action

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall

X

Almirall gets in on the eczema action

https://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/

Deep Dive: Access and Commercialisation

Deep Dive: Access and Commercialisation

In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing

X

Deep Dive: Access and Commercialisation

https://pharmaphorum.com/digital/pharma-access-commercialisation/

LEO Pharma teams up with Wearifi for dermatology research wearable

LEO Pharma teams up with Wearifi for dermatology research wearable

LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential

X

LEO Pharma teams up with Wearifi for dermatology research wearable

https://pharmaphorum.com/news/leo-pharma-wearifi-dermatology/

Almirall buys Allergan’s derma portfolio

Almirall buys Allergan’s derma portfolio

Almirall is expanding its business by buying Allergan’s dermatology portfolio. The Spanish pharma company will buy five brands

X

Almirall buys Allergan’s derma portfolio

https://pharmaphorum.com/news/almirall-buys-allergans-derma-portfolio/

LEO Pharma acquires Bayer’s dermatology unit

LEO Pharma acquires Bayer’s dermatology unit

Danish LEO Pharma announced yesterday (July 31st) that it has entered a binding agreement to purchase Bayer’s global

X

LEO Pharma acquires Bayer’s dermatology unit

https://pharmaphorum.com/news/leo-pharma-acquires-bayers-dermatology-unit/

The sky’s the limit for LEO Pharma’s R&D hub

The sky’s the limit for LEO Pharma’s R&D hub

As part of pharmaphorum’s eye-on-innovation series of interviews, Richard Staines speaks to Michael Sierra, Vice President of LEO

X

The sky’s the limit for LEO Pharma’s R&D hub

https://pharmaphorum.com/views-analysis-digital/skys-limit-leo-pharma-rd-hub/

Novartis ranked top for corporate reputation in dermatology

Novartis ranked top for corporate reputation in dermatology

Novartis has been ranked the top pharma company in dermatology in a corporate reputation survey of skin condition

X

Novartis ranked top for corporate reputation in dermatology

https://pharmaphorum.com/news/novartis-corporate-reputation-dermatology/

Leo and VCCP’s psoriasis campaign tops winners at PM Society Awards

Leo and VCCP’s psoriasis campaign tops winners at PM Society Awards

Two moving films highlighting serious health issues have won top honours at this year’s PM Society Awards in London.

X

Leo and VCCP’s psoriasis campaign tops winners at PM Society Awards

https://pharmaphorum.com/news/leo-vccps-psoriasis-campaign-top-winners-pm-society-awards/

AZ suing US regulator to prevent Crestor generics

AZ suing US regulator to prevent Crestor generics

Firm also licenses two dermatology drugs to LEO Pharma.

X

AZ suing US regulator to prevent Crestor generics

https://pharmaphorum.com/news/az-suing-us-regulator-prevent-crestor-generics/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com